Aldevron announced today the immediate availability of rep/cap plasmids pALD-AAV2, AAV5 and AAV6 to support AAV viral vector manufacturing. All three rep/cap plasmids are immediately available at Research Grade. Additionally, pALD-AAV6 is immediately available at the GMP-Source® quality level, while pALD-AAV2 and pALD-AAV5 will be made available based on market demand. The plasmids are royalty free for all applications in support of pre-clinical activities through clinical development and commercial production.

The Joint Session of the State of North Dakota’s 67^th Legislative Assembly held its opening sessions earlier this week, and featured Governor Doug Burgum’s 2021 State of the State address. Burgum reflected on the progress and challenges of the past year, calling for bold action and investments in infrastructure and other priorities to position the state for a bright future.

Aldevron, a global leader in the manufacture of plasmid DNA, mRNA and proteins, announced the appointment of Matt Johnson as Vice President of Information Technologies (IT). In this newly-created executive role, Johnson will lead the IT team to ensure successful implementation and operation of key technology strategies.

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced today that it has successfully completed the technology transfer of its manufacturing process for the production of REQORSA™ immunogene therapy, the company’s lead drug candidate.

Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, announced the appointment of Kevin Ballinger to its Board of Directors.

Plasmid DNA was key to the development of biologic drug manufacturing. Today, it plays a critical role in the production of next-generation cell and gene therapies and vaccines. With its plasmid DNA manufacturing expertise, Aldevron has helped facilitate the advance of these important therapeutics. The company continues to invest in additional capacity and novel capabilities to support biopharma manufacturers into the future.

Aldevron today announced it ranked 287 on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies in North America now in its 26th year. Aldevron’s growth surpassed all expectations during this period.

Aldevron, a global leader in the manufacture of plasmid DNA, mRNA and proteins, today announced Shawn McCormick as its Chief Financial Officer. He will begin this new role immediately and will be a member of Aldevron’s executive team reporting to CEO Kevin Ballinger. 

The Technology Council of North Dakota (TechND) named Aldevron one of three leading businesses within the technology sector, emphasizing its achievements and contributions to the biotech industry through innovation and expertise.

Aldevron, a global leader in the manufacture of plasmid DNA, mRNA and proteins, has promoted Venkata Indurthi to Vice President of Research and Development (R&D).  He will begin this new role immediately and continue reporting to John Ballantyne, Co-founder and Chief Scientific Officer while having direct access to Aldevron’s senior executive team.